Legal & General Group
IKT icon

Legal & General Group’s Inhibikase Therapeutics IKT Stock Holding History

Legal & General Group’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5K Buy
12,078
+2,674
+28% +$4.79K ﹤0.01% 3036
2026
Q1 		$15.8K Buy
9,404
+3,900
+71% +$6.92K ﹤0.01% 3048
2025
Q4 		$11.3K Hold
5,504
– – ﹤0.01% 3219
2025
Q3 		$8.89K Hold
5,504
– – ﹤0.01% 3311
2025
Q2 		$10.7K Buy
+5,504
New +$10.8K ﹤0.01% 3268

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Legal & General Group's IKT Position: Q2 2026 in Review

Legal & General Group increased its Inhibikase Therapeutics (IKT) stake by 28% in Q2 2026, buying an estimated $4.79K and bringing the position to 12,078 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3036.

Legal & General Group first reported a position in IKT in Q2 2025 and has held it in 5 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Legal & General Group held 12,078 shares of Inhibikase Therapeutics worth $24.5K as of Q2 2026.
  • Legal & General Group bought 2,674 Inhibikase Therapeutics shares in Q2 2026, an estimated $4.79K.
  • Inhibikase Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3036 holding.
  • Legal & General Group first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.